Literature DB >> 1860074

Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat.

P Marek1, S Ben-Eliyahu, M Gold, J C Liebeskind.   

Abstract

To investigate the possible role of excitatory amino acids (EAAs) in the mechanisms of morphine tolerance, rats were treated either with the wide-spectrum EAA antagonist, kynurenic acid (150 mg/kg), or the specific N-methyl-D-aspartic acid (NMDA) receptor antagonist. MK-801 (0.05 mg/kg), during a four-day induction period of morphine tolerance. Morphine was given once daily at a dose of 15 mg kg. On the fifth day rats were injected only with morphine (15 mg/kg), and analgesia was assessed using the hot-plate test. Morphine tolerance was significantly reduced by both EAA antagonists. Control experiments showed that at the same doses neither acute nor chronic administration of these antagonists affected morphine analgesia itself in a manner that can explain these findings. The possible involvement of EAAs in the mechanisms of morphine tolerance is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860074     DOI: 10.1016/0006-8993(91)90576-h

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  32 in total

Review 1.  Roles of reactive oxygen and nitrogen species in pain.

Authors:  Daniela Salvemini; Joshua W Little; Timothy Doyle; William L Neumann
Journal:  Free Radic Biol Med       Date:  2011-01-28       Impact factor: 7.376

2.  Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization.

Authors:  Shoshana Eitan; Camron D Bryant; Nazli Saliminejad; Yu C Yang; Elroy Vojdani; Duane Keith; Roberto Polakiewicz; Christopher J Evans
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

3.  Chronic, but not acute morphine treatment, up-regulates alpha-Ca2+/calmodulin dependent protein kinase II gene expression in rat brain.

Authors:  Yuejun Chen; Yan Jiang; Wen Yue; Yuqing Zhou; Lin Lu; Lan Ma
Journal:  Neurochem Res       Date:  2008-04-12       Impact factor: 3.996

Review 4.  Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?

Authors:  Z Wiesenfeld-Hallin
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 5.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

Review 6.  Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Authors:  Ian D Meng; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2011-03-28       Impact factor: 6.292

7.  Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice.

Authors:  P Popik; E Kozela; A Pilc
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

8.  The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice.

Authors:  E Del Pozo; M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

9.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

10.  Ascorbic Acid inhibits development of tolerance and dependence to opiates in mice: possible glutamatergic or dopaminergic modulation.

Authors:  S K Kulkarni; C Deshpande; A Dhir
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.